Endocannabinoid Tone (ECT)

Endocannabinoid tone refers to the baseline level of endocannabinoid system activity in a given tissue or organism, determined by the local concentrations of endocannabinoids, the expression density of their receptors, and the rate of their enzymatic synthesis and degradation.

The endocannabinoid system (ECS) does not operate in an all-or-nothing fashion. At any given moment, tissues maintain a resting level of signalling activity shaped by three interacting variables: the ambient concentrations of the primary endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG); the expression levels and functional availability of CB₁ and CB₂ receptors (and, to a lesser extent, ancillary targets such as TRPV1 and GPR55); and the enzymatic machinery governing synthesis and breakdown , principally NAPE-PLD and FAAH for AEA, and DAGL/MAGL for 2-AG. Tone is therefore not a single number but a tissue-specific, dynamic steady-state.

Because endocannabinoid signalling is largely retrograde , released from postsynaptic neurons to act on presynaptic terminals , local tone exerts a modulatory influence on neurotransmitter release at a given synapse. The same principle applies in peripheral tissues, where resident CB₂ receptors on immune cells respond to fluctuating local endocannabinoid concentrations. Measured tone consequently differs between brain regions, gut, skin, and reproductive tissue, among others.

A number of researchers have proposed the Clinical Endocannabinoid Deficiency (CED) hypothesis, which posits that sub-optimal endocannabinoid tone may be associated with certain physiological states. This remains a working hypothesis: the evidence base, reviewed in Russo (2016) in Cannabis and Cannabinoid Research, is largely indirect and observational, and the hypothesis has not been validated through prospective controlled trials. It should not be read as an established mechanistic explanation for any clinical condition.

Endocannabinoid tone is also context-sensitive. It can shift in response to factors including diet (particularly dietary fatty acid composition, which influences endocannabinoid precursor availability), exercise, stress, and ageing. Exogenous cannabinoids; both phytocannabinoids and synthetic compounds, interact with the same receptor pool and thereby alter effective tone, which underlies much of the pharmacological interest in the ECS. In Australia, medicinal cannabis products that act on CB₁/CB₂ receptors are regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989 and are Schedule 4 (prescription-only) or Schedule 8 (controlled drug) substances under the Poisons Standard.

Sources: